Physician profile
Dylan Iorio
NPI 1083431191
$3,114.96
in general payments reported to CMS, 2019-2025
24 companies · $2,867 in 2025
The $2,867 reported for 2025 was more than what 99% of Pediatrics (Nurse Practitioner) providers received nationally (typical 2025 total: $93.49).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $248 · 2025: $2,867.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,115.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,114.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $497.28 | 2024-2025 | Fintepla, Nayzilam, Briviact |
| Neurelis, INC. | $369.87 | 2024-2025 | Valtoco |
| Catalyst Pharmaceuticals, INC. | $354.19 | 2024-2025 | |
| Aucta Pharmaceuticals, INC. | $256.25 | 2025 | Motpoly Xr |
| Jazz Pharmaceuticals INC. | $240.44 | 2025 | |
| Alexion Pharmaceuticals, INC. | $207.88 | 2025 | Koselugo |
| Itf Therapeutics LLC | $161.64 | 2024-2025 | |
| Biocodex, INC. | $161.27 | 2025 | |
| Springworks Therapeutics, INC. | $139.34 | 2025 | Ogsiveo, Gomekli |
| Verrica Pharmaceuticals INC. | $123.35 | 2025 | Ycanth |
| Biogen, INC. | $111.93 | 2025 | Spinraza, Skyclarys |
| Upsher-Smith Laboratories LLC | $72.65 | 2025 | |
| Azurity Pharmaceuticals, INC. | $63.28 | 2025 | Zonisade, Zenzedi |
| Genentech USA, INC. | $54.36 | 2025 | Evrysdi |
| Sarepta Therapeutics, INC. | $54.01 | 2024-2025 | Elevidys |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ns Pharma, INC. | $50.52 | 2025 | Viltepso |
| Livanova USA, INC. | $49.50 | 2025 | Vns Therapy Sentiva Model 1000 Generator |
| Mirum Pharmaceuticals, INC. | $24.97 | 2025 | Cholbam |
| Sk Life Science, INC. | $21.95 | 2025 | |
| Janssen Biotech, INC. | $21.70 | 2025 | |
| Ipsen Biopharmaceuticals, INC | $21.47 | 2025 | Dysport |
| Novartis Pharmaceuticals Corporation | $21.08 | 2024 | |
| Supernus Pharmaceuticals, INC. | $18.17 | 2025 | Qelbree |
| Nobelpharma America, LLC | $17.86 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dylan Iorio listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.